Precision Medicine Online10d
Aprea, MD Anderson Cancer Center Partner to Study WEE1 Kinase Inhibitor in Certain Head and Neck Cancers
The collaboration will explore the potential of APR-1051 as a therapy for head and neck cancers bearing markers of replication stress.
pharmaphorum7y
Researchers start trial on AZ WEE1 drug in head and neck cancer
UK researchers have begun an early stage clinical trial on AstraZeneca's experimental drug from the new WEE1 kinase drug class in head and neck cancer. The Combinations Alliance – a joint ...
Yahoo Finance14d
Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti ...
BioWorld12d
Mindrank’s dual WEE1 and YES1 kinase inhibitor cleared to enter clinic in US
Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...